<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
<title>TFM. Máster en Biología y Clínica del Cáncer</title>
<link href="http://hdl.handle.net/10366/150475" rel="alternate"/>
<subtitle/>
<id>http://hdl.handle.net/10366/150475</id>
<updated>2026-04-22T05:38:35Z</updated>
<dc:date>2026-04-22T05:38:35Z</dc:date>
<entry>
<title>Study of IGH sequences in low-count monoclonal B-cell lymphocytosis</title>
<link href="http://hdl.handle.net/10366/150482" rel="alternate"/>
<author>
<name>Serrano Lozano, José Manuel</name>
</author>
<id>http://hdl.handle.net/10366/150482</id>
<updated>2025-04-30T21:51:05Z</updated>
<published>2022-01-01T00:00:00Z</published>
<summary type="text">Low-count monoclonal B-cell lymphocytosis (MBLlo) is defined by the presence of&#13;
&lt;0.5 × 10! clonal B-cells/L in blood in the absence of any other symptoms or signs of a&#13;
neoplastic lymphoproliferative disorder. It is still unclear whether MBLlo represents a pre-&#13;
malignant state prior to chronic lymphocytic leukemia (CLL) or it relates to a physiological&#13;
immunosenescent process. The molecular and biochemical characteristics of the B-cell&#13;
receptor (BCR) including the specific immunoglobulin heavy-chain (IGH) sequences&#13;
have been related to disease behavior in CLL. In MBLlo, few studies have been reported&#13;
of IGH sequences on the clonal B-cells, mostly due to their low counts in blood.&#13;
Here, we set up a workflow adapted to the low MBLlo clonal B-cell numbers aimed at&#13;
more efficiently characterize genetically and molecularly the IGHV rearrangements of&#13;
the BCR of MBLlo cases. We also compare genetic and molecular characteristics of the&#13;
BCR of MBLlo vs MBLhi and CLL B-cell clones, and their impact on the behavior of MBLlo&#13;
clonal B-cells during follow-up.&#13;
MBLlo clonal B-cells were isolated from blood of otherwise healthy individuals by high-&#13;
sensitive flow cytometry. Two different multiplex PCR protocols for IGHV sequencing&#13;
were applied, depending on the number of MBLlo clonal B-cells available, using a&#13;
threshold of 50,000 cells for protocol selection.&#13;
The new workflow set up allowed us to increase the number of MBLlo cases included in&#13;
out cohort (N=34), for subsequent comparison of IGHV sequences to two MBLhi (N=73)&#13;
and CLL (N=138) cohorts. The IGHV3-7 gene sequence was more frequently found in&#13;
MBLlo subjects, whereas IGHV3-23 was highly represented in MBLhi patients. No&#13;
significant differences were reported in D segments, while IGHJ4 was significantly more&#13;
frequent in MBLlo and IGHJ6 in CLL. Compared to other J-gene segments, clonal B-cells&#13;
with IGHJ6 show a more immature origin and present longer HCDR3 sequences.&#13;
Nevertheless, this BCR characteristic showed no significant impact in the behavior of the&#13;
MBLlo clone during follow-up; however a tendency towards a greater size of MBLlo clones&#13;
was observed among IGHJ6 cases.&#13;
The new workflow here proposed proved to be a useful tool to increase the efficiency of&#13;
the characterization of the BCR sequences of MBLlo cases with low clonal B-cells&#13;
numbers revealing unique BCR sequences vs MBLhi and CLL.
</summary>
<dc:date>2022-01-01T00:00:00Z</dc:date>
</entry>
</feed>
